Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 217 points (1.3%) at 16,418 as of Friday, Sept. 25, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,782 issues advancing vs. 1,190 declining with 158 unchanged.

The Health Services industry currently sits down 1.2% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Cigna ( CI), down 1.3%, Medtronic ( MDT), down 0.8% and Abbott Laboratories ( ABT), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. CR Bard ( BCR) is one of the companies pushing the Health Services industry higher today. As of noon trading, CR Bard is up $2.18 (1.1%) to $197.20 on light volume. Thus far, 205,625 shares of CR Bard exchanged hands as compared to its average daily volume of 581,500 shares. The stock has ranged in price between $195.33-$198.23 after having opened the day at $196.29 as compared to the previous trading day's close of $195.02.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard has a market cap of $14.5 billion and is part of the health care sector. The company has a P/E ratio of 43.5, above the S&P 500 P/E ratio of 24.3. Shares are up 17.0% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate CR Bard a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates CR Bard as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full CR Bard Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Stryker Corporation ( SYK) is up $0.57 (0.6%) to $98.79 on average volume. Thus far, 544,667 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $98.55-$99.45 after having opened the day at $98.88 as compared to the previous trading day's close of $98.22.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. Stryker Corporation has a market cap of $37.1 billion and is part of the health care sector. The company has a P/E ratio of 40.4, above the S&P 500 P/E ratio of 24.3. Shares are up 4.1% year-to-date as of the close of trading on Thursday. Currently there are 16 analysts who rate Stryker Corporation a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Stryker Corporation Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is up $0.86 (0.7%) to $124.86 on average volume. Thus far, 674,740 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $124.37-$125.36 after having opened the day at $124.66 as compared to the previous trading day's close of $124.00.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. Thermo Fisher Scientific has a market cap of $49.7 billion and is part of the health care sector. The company has a P/E ratio of 25.5, above the S&P 500 P/E ratio of 24.3. Shares are down 1.0% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Thermo Fisher Scientific Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).